ANTIVIRAIS DE AÇÃO DIRETA NO TRATAMENTO DA HEPATITE C: FATORES ASSOCIADOS COM A RESPOSTA VIROLÓGICA

• Autor(a) principal: Tiroli, Carla Fernanda
• Data de Publicação: 2022
• Outros Autores: Furuya, Rejane Kiyomi, Dias, Douglas Fernando, Galhardi , Lígia Carla Faccin, Bolorino, Natacha, Arcoverde, Marcos Augusto Moraes, Novaes , Andressa Cristina, Pieri, Flávia Meneguetti
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Saúde (Santa Maria)
• Texto Completo: https://periodicos.ufsm.br/revistasaude/article/view/69186
• topic: Hepatite C Crônica; Infecções; Resposta Viral Sustentada; Antivirais; Epidemiologia.

Objective: To analyze the factors associated with the sustained virologic response (SVR) in the direct-acting antivirals treatment in hepatitis C virus (HCV) patients. Method: Analytical cross-sectional study, from 2015 to 2019. For bivariate analysis Pearson's Chi-Square and Fisher's Exact tests were performed, adopting a value of p ≤ 0.05. Results: A total of 244 cases were analyzed, and a statistically significant association was found with SVR, the Sofosbuvir and Daclatasvir therapeutic scheme. Regarding the genotype (GT) type, GT1 presented high SVR, while GT3 had less response. There was no association between liver disease staging and viral load. Conclusion: Sofosbuvir and Daclatasvir was the only therapeutic scheme that showed a statistically significant association; GT1 had high SVR, while in GT 3 SVR was lower. There was no association between liver disease staging and viral load.